

European Respiratory Society Annual Congress 2013

Abstract Number: 605

Publication Number: 3524

Abstract Group: 1.5. Diffuse Parenchymal Lung Disease

Keyword 1: Interstitial lung disease **Keyword 2:** Bronchoalveolar lavage **Keyword 3:** Immunology

Title: Expression of immunoproteasome subunits LMP2 and LMP7 by alveolar macrophages is reduced in patients with idiopathic pulmonary fibrosis

Dr. Xuan 4823 He 445938738@163.com MD ¹, Dr. Francesco 4824 Bonella Francesco.Bonella@ruhrlandklinik.uk-essen.de MD ¹, Dr. Miao-tian 4825 Cai cici0511@sina.com MD ^{1,2}, Prof. Dr Toshio 4826 Mori tmori@naramed-u.ac.jp MD ³, Prof. Dr Josune 4827 Guzman Josune.Guzman@rub.de MD ⁴ and Prof. Dr Ulrich 4828 Costabel ulrich.costabel@ruhrlandklinik.uk-essen.de MD ¹. ¹ Department of Pneumology /Allergology, Ruhrlandklinik, University Hospital, University Duisburg-Essen, Essen, Germany ; ² Department of Infectious Disease, Beijing You'an Hospital, Capital Medical University, Beijing, China ; ³ Radioisotope Research Center, Nara Medical University, Kashihara, Japan and ⁴ General and Experimental Pathology, Ruhr University, Bochum, Germany .

Body: Rationale: Proteasomes are involved in the degradation of ubiquitinated proteins and the MHC I-restricted antigen presentation. Low molecule weight protein (LMP) 2 and LMP7 are interferon γ -inducible and catalytic subunits of 20S proteasome, and turn it to immunoproteasome. This study was aimed to compare the expression of LMP2 and LMP7 in alveolar macrophages (AMs) from patients with idiopathic pulmonary fibrosis (IPF) and cryptogenic organized pneumonia (COP). Methods: BAL cells were collected from 31 patients: 12 IPF, 11 COP and 8 control subjects. Immunocytochemistry was used to stain the cells with monoclonal antibodies against LMP2 and LMP7. Proportions of LMP2 and LMP7 positive AMs were calculated and the strength of LMP2 and LMP7 expression was estimated semi-quantitatively by a staining-intensity score system. Results: The expression of LMP2 and LMP7 by AMs from IPF patients was significantly decreased in comparison to controls (Table 1): for COP only a tendency was seen. The expression of LMP7 but not LMP2 in IPF patients treated with steroids was significantly higher compared with those without steroids (positive rates, $p=0.026$; scores, $p=0.003$). Conclusions: The expression of the immunoproteasome subunits seems to be reduced in IPF. The influence of steroid therapy on the expression of LMP7 cannot be excluded.

Table1. Expression of immunoproteasome subunits by AMs in the studied groups

| Immunoproteasome subunits | | Controls (N=8) | IPF (N=12) | COP (N=11) |
|---------------------------|-------------------|----------------|------------|------------|
| LMP2 | Positive Rate (%) | 47±24 | 20±22* | 40±33 |
| | Score | 49±25 | 20±22* | 47±45 |

| | | | | |
|------|-------------------|-------|--------|--------|
| LMP7 | Positive Rate (%) | 84±8 | 58±39* | 57±39* |
| | Score | 97±19 | 77±61 | 76±63 |

*: p<0.05 vs. controls.